Epoch Biosciences, Nanogen deal

NGEN will acquire EBIO for $58 million in stock. NGEN said the deal will expand its offerings for the clinical lab and research markets and allow it to offer additional in vitro diagnostics and reagents. NGEN said it already is integrating EBIO's MGB Eclipse Probe System of reagents and software for molecular analyses into NGEN's assays. NGEN expects that EBIO will provide a cash flow positive contribution to its business. For the six months ended June 30, EBIO posted an operating loss of $1.4 million on revenues of $3.9 million and had $9.2 million in cash. ...